Results 11 to 20 of about 19,315 (197)
Reactions Weekly, 2013 Antiplatelet drugs are the cornerstone of treatment for patients with acute coronary syndromes (ACS) who undergo percutaneous coronary intervention. Clopidogrel and aspirin improve long-term clinical outcomes in these patients and have become a standard ...
Gianluca Airoldi, Mauro Campanini
core +3 more sources
Critical appraisal of ticagrelor in the management of acute coronary syndrome
Therapeutics and Clinical Risk Management, 2011 James J Nawarskas, Stanley S SnowdenUniversity of New Mexico College of Pharmacy, Albuquerque, NM, USAAbstract: Ticagrelor is a novel P2Y12 receptor antagonist which, like clopidogrel and prasugrel, functions by blocking adenosine diphosphate-mediated ...
Nawarskas JJ, Snowden SS
doaj +1 more source
Ticagrelor — a legend of modern cardiology
Российский кардиологический журналThe article presents the evidence on the basis of which the ticagrelor is used in patients with various forms of coronary artery disease, including both acute and chronic.
S. R. Gilyarevsky
doaj +3 more sources
Ticagrelor – toward more efficient platelet inhibition and beyond
Therapeutics and Clinical Risk Management, 2018 Michał J Kubisa,1 Mateusz P Jezewski,1 Aleksandra Gasecka,2,3 Jolanta M Siller-Matula,4 Marek Postuła1 1Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology (CEPT), 21st Chair and Department of Cardiology,
Kubisa MJ +4 more
doaj +1 more source
Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis
Drug Design, Development and Therapy, 2016 Michael R Preusch,1 Jonas Rusnak,1 Kathrin Staudacher,2 Carolin Mogler,3 Lorenz Uhlmann,4 Philipp Sievers,1 Florian Bea,1 Hugo A Katus,1 Erwin Blessing,1 Ingo Staudacher1 1Department of Internal Medicine III, 2Department of Neonatology, 3Department of ...
Preusch MR +9 more
doaj +1 more source
Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal
Periodontology 2000, EarlyView., 2023 Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra +3 more
wiley +1 more source
, 2022 S.313-323The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor.
Almquist, J. +9 more
core +2 more sources
Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. [PDF]
PLoS ONE, 2017 Data from available studies suggest that the presence of ST-elevation myocardial infarction (STEMI) may be associated with delayed and attenuated ticagrelor bioavailability and effect compared with non-ST-elevation myocardial infarction (NSTEMI).In a ...
Piotr Adamski +16 more
doaj +1 more source
Platelets, 2019 We performed this study to observe the effects of different doses of ticagrelor and standard-dose clopidogrel on platelet reactivity and endothelial function in diabetic patients with stable coronary artery disease (CAD).
Meijiao He +9 more
doaj +1 more source
Ticagrelor induced systemic inflammatory response syndrome [PDF]
, 2017 Background Ticagrelor is a reversible and direct-acting oral antagonist of the adenosine diphosphate receptor P2Y12. Possible adenosine-mediated effects of ticagrelor on inflammation are complex and incompletely understood.
Buser, Peter +9 more
core +1 more source